Trial Profile
Dolutegravir Plus Rilpivirine as a Switch Option in cART-Experienced Patients: 96-Week Data.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Mar 2018
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary) ; Rilpivirine (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- 09 Mar 2018 New trial record
- 01 Feb 2018 Results published in the Annals of Pharmacotherapy